]>
IRCT2013072314122N1 IRCT 2013-12-28 Kurdistan University of Medical Sciences Efficacy of Memantine on Cognitive Performance of Patients Under Electro Convulsive Therapy Efficacy of Memantine on Cognitive Performance of Patients Under Electro Convulsive Therapy 2014-07-23 anticipated 40 Other https://irct.ir/trial/13807 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment. N/A Condition 1: Mental and behavioural disorders. Condition 2: Mental and behavioural disorders. Condition 3: Mental and behavioural disorders. Condition 4: Mental and behavioural disorders. Condition 5: Mental and behavioural disorders. Condition 6: Mental and behavioural disorders. Intervention 1: cap memantine first day 5 mg capsule twice a day and the second day, three times a day, then 10 mg capsule twice a day (morning and night) until the end of ECT treatment. Intervention 2: Placebo capsules, starch capsules 5 mg in the morning and evening of the first day, second day morning noon and night and then 10 mg capsules morning and night until the end of ECT treatment.
public Azad Maroufi
Pasdaran street below the Pardis, Ghods hospital, Sanandaj
Sanandaj Iran (Islamic Republic of) 66177_13446 +98 87 1666 4646 marufi@muk.ac.ir Kurdistan University of Medical Sciences scientific Azad Maroufi
Pasdaran street below the pardis, Ghods hospital, Sanandaj
Sanandaj Iran (Islamic Republic of) 66177_13446 +98 87 1666 4646 maroufi@muk.ac.ir Kurdistan University of Medical Sciences Iran (Islamic Republic of) This study was done on patients in Sanandaj in 1392 in Qods hospital admissions and physician elected to receive ECT. Inclusion criteria: Patients between 60-18 years of age who are candidates for ECT; Patient or legal guardian to sign an informed consent form; Number of ECT sessions is between 4 to 12 sessions; Location is the city of Sanandaj. Exclusion criteria: Abuse or dependence on alcohol and drugs during the 3 months prior to admission (excluding nicotine or caffeine); Proven kidney disease (Renal Failure proven); Epilepsy; Mental Retardation based on clinical evaluation Resident Project; Delirium, Dementia and Cognitive disorders; Pregnancy and lactation; Use of Memantine than 3 months prior to admission; Patients who are receiving Thiazide diuretics; History of allergic symptoms and side effect with Memantine. 18 years 60 years Both F20-F21-F2 F30-F31-F3 F40-F41-F4 Disorders Disorders F99 Schizophrenia, schizotypal and delusional disorders Mood [affective] disorders Neurotic, stress-related and somatoform disorders F60-F61-F62-F63-F64-F65-FF66-F67-F68-F69 F60-F61-F62-F63-F64-F65-FF66-F67-F68-F69 Unspecified mental disorder Treatment - Drugs Treatment - Drugs cap memantine first day 5 mg capsule twice a day and the second day, three times a day, then 10 mg capsule twice a day (morning and night) until the end of ECT treatment Placebo capsules, starch capsules 5 mg in the morning and evening of the first day, second day morning noon and night and then 10 mg capsules morning and night until the end of ECT treatment Cognitive function. Timepoint: ECT prior to and after completion of the. Method of measurement: MMSE and Digit Span Test. Duration of the sizure. Timepoint: During ECT sessions. Method of measurement: View and review patient records. Delayed onset sizure. Timepoint: Electric convulsive therapy during hospital stay. Method of measurement: patients visit and file check. Kurdistan University of Medical Sciences Approved 2013-09-18 Kurditan University of Medical Sciences Pasdaran Ave., Quds hospital campus Sanandaj Iran (Islamic Republic of)